ГоловнаArchive of numbers2020Volume 28, issue 3 (104)Immune predictors in acute phase of ischemic stroke
Title of the article Immune predictors in acute phase of ischemic stroke
Authors Lychko Volodymyr
In the section MECHANISMS OF FORMATION AND MODERN PRINCIPLES OF TREATMENT OF NEUROLOGICAL DISORDERS
Year 2020 Issue Volume 28, issue 3 (104) Pages 12-15
Type of article Scientific article Index UDK 616.831-005.8-036.1 Index BBK -
Abstract DOI:https://doi.org/10.36927/2079-0325-V28-is3-2020-2

The acute phase of ischemic stroke (IS) is always accompanied by significant changes in the cytokine status of patients, which affects the further course of disease, determines the severity and prognosis. The purpose of the research was to study complex features peculiarities of changes in cytokine profile in patients of various degrees of severity in the acute phase of IS to optimize diagnosis and identify new prognostic factors. Immunological monitoring of 350 patients with IS was performed to determine the plasma levels of main pro- and anti-inflammatory cytokines. The results of the study showed high levels of these substances in debut of IS and in dynamics of the disease, which determined the severity of patients. The data obtained allowed us to develop new prognostic criteria for severity in the acute phase of IS. The levels of proinflammatory (interleukin-6 (IL-6) and TNF-α) and anti-inflammatory cytokines (IL‑4 and IL‑10) in the serum of 350 patients with IS during hospitalization on the 1st, 10th and 21st day of treatment were performed. The plasma concentration of IL-6 in the debut of the disease can reach 32.75 ± 3.44 pg/ml. The levels from 34.77 ± 2.9 pg/ml to 35.26 ± 1.96 pg/ml indicate the severity of local inflammatory response. The levels of TNF-α at day 1 reaches 16.13 ± 0.77 pg/ml unfavorable for the forecast should be considered concentrations within 18,69 ± 0,64 — 18,87 ± 0,83 pg/ml. On the 1st day, the concentration of IL-4 can reach 4.51 ± 1.67 pg/ml, and IL‑10 — 2.36 ± 0.31 pg/ml. High levels of IL‑4 in serum from 5.15 ± 1.17 pg/ml to 5.42 ± 0.27 pg/ml, and IL-10 from 2.48 ± 0.33 pg/ml to 2.57 ± 0.11 pg/ml can indicate a significant intensity of inflammatory processes in the lesion area, which is also always adversely affected by the outcome of the disease.
Key words cytokine, interleukin, acute phase, inflammation, predictor
Access to full text version of the article pdf download
Bibliography 1. Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK / Armstead W. M., Hekierski H., Pastor P. [et al.] // Translational Stroke Research. 2019. Vol. 10, no. 1. P. 104—111. DOI: 10.1007/s12975-018-0617-z.
2. IL-6 Plasma Levels Correlate With Cerebral Perfusion Deficits and Infarct Sizes in Stroke Patients Without Associated Infections / Hotter B., Hoffmann S., Ulm L. [et al.] // Frontiers in Neurology. 2019. Vol. 10. P. 1—8. DOI: 10.3389/fneur.2019.00083.
3. Microglia-derived TNF-alpha mediates endothelial necroptosis aggravating blood brain-barrier disruption after ischemic Stroke / Chen A. Q., Fang Z., Chen X. L. [et al.] // Cell Death & Disease. 2019. Vol. 10. P. 1—18. DOI: 10.1038/s41419-019-1716-9.
4. Anrather J., Iadecola C. Inflammation and Stroke: An Overview // Neurotherapeutics. 2016. Vol. 13, no. 4. P. 661—670. DOI: 10.1007/s13311-016-0483-x.
5. Inflammatory Markers and Outcomes After Lacunar Stroke Levels of Inflammatory Markers in Treatment of Stroke Study / Boehme A. K., McClure L. A., Zhang Y. [et al.] // Stroke. 2016. Vol. 47, no. 3. P. 659—667. DOI: 10.1161/strokeaha.115.012166.
6. Role of interleukin-10 in Acute Brain injuries / Garcia J. M., Stillings S. A., Leclerc J. L. [et al.] // Frontiers in Neurology. 2017. Vol. 8. DOI: 10.3389/fneur.2017.00244.
7. Changes in the cellular immune system and circulating inflammatory markers of stroke patients / Jiang C., Kong W. X., Wang Y. J. [et al.] // Oncotarget. 2017. Vol. 8, no. 2. P. 3553—3567. DOI: 10.18632/oncotarget.12201.
8. Lively S., Hutchings S., Schlichter L. C. Molecular and Cellular Responses to Interleukin-4 Treatment in a Rat Model of Transient Ischemia // Journal of Neuropathology and Experimental Neurology. 2016. Vol. 75, no. 11. P. 1058—1071. DOI: 10.1093/jnen/nlw081.
9. Baseline NIH Stroke Scale is an inferior predictor of functional outcome in the era of acute stroke intervention / Reznik M. E., Yaghi S., Jayaraman M. V. [et al.] // International Journal of Stroke. 2018. Vol. 13, no. 8. P. 806—810. DOI: 10.1177/1747493018783759.
10. Link between Interleukin-10 Level and Outcome after Ischemic Stroke / Chang L. T., Yuen C. M., Liou C. W. [et al.] // Neuroimmunomodulation. 2010. Vol. 17, no. 4. P. 223—228. DOI: 10.1159/000290038.